Readers who invested into various psychedelic stocks late last year were rewarded with enormous gains.
Take for instance:
MindMed (NEO: MMED) from 0.40 to $6.40 in just over four months.
Core One Labs (CSE: COOL, OTC: CLABF) from $2.50 to $11.80 in three months.
Numinus (CSE: NUMI, OTC: LKYSF) from $0.185 to $2.45 in four months.
Cybin (NEO: CYBN, OTC: CLXPF) from 0.64 to $4.00 in eight months.
Company's involved in psychedelic-assisted therapy and innovation in this emerging sector are beginning to command large market caps and the best run company's continue to produce impressive gains for investors.
Here's why we think this stock could be the next high flyer in the psychedelic sector.
The global mental health crisis is staggering in size, costing the world economy an estimated $8 trillion USD from depressive disorders (1). The anxiety disorder and depressive treatment market size is $238 billion USD (2) with an estimated annual spend of $16 billion USD (3) on mental health and ancillary services.
KETAMINE ONE (OTC: KONEF | NEO: MEDI) is consolidating the highly fragmented North American clinic industry and rapidly scaling its business to become a major player in the multi-billion dollar psychedelic-assisted therapy sector. Their business model incorporates a growing roster of clinics, telemedicine, contract research and digital therapeutics including novel wearable devices such as guided Immersive Virtual Reality.
As legalization rolls out across North America, the psychedelic-assisted therapy sector is exploding with growth and ketamine clinics have arguably become the most profitable vertical in the space.
90 SECOND INVESTOR SUMMARY
Massive market seeking effective therapies
"As a result of KetamineOne's existing clinical platform and KGK's complementary research capabilities, we are well positioned to capitalize on the inflow of capital and talent to psychedelics focused companies." - Najla Guthrie, president and chief executive officer of KGK, wholly owned subsidiary of KetamineOne.
CLICK BELOW TO VIEW KETAMINEONE's COMPLETE INVESTOR PRESENTATION
The Daily Dive interviews Adam Deffett, CEO of KetamineOne Capital (NEO: MEDI). Adam discusses the strategy behind Ketamine One and how it relates to recent acquisitions, the move to the NEO exchange, IVR therapies, and the future of the ketamine space as a whole.
 Patel, Ankit & Saxena, et al. (2018). The Lancet Commission on global mental health and sustainable development. The Lancet. 392. 10.1016/S0140-6736(18)31612-X.
 Substance Abuse and Mental Health Services Administration, Projections of National Expenditures for Treatment of Mental and Substance Use Disorders, 2010-2020.
HHS Publication No. SMA-14-4883. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014
 Global Newswire, Reports and Data, May 2019
The MicrocapBull.com (“MB”) website is owned by Mountain Capital Corp. (“Mountain Capital”).
Those terms include your acknowledgement that: (i) MB is neither an investment adviser nor a broker-dealer; (ii) the information presented on this website is for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment; (iii) you should consult with a registered investment advisor or financial advisor before making any investment decisions; and (iv) MB provides readers with information regarding publicly traded companies that may have paid a fee to MB to provide promotional services on their behalf, or of which MB and its directors, officers, or employees may own securities.
Pursuant to an agreement between KetamineOne Capital (“Company”) and Mountain Capital, Mountain Capital has been hired to publicly disseminate information about the Company via digital communications. Mountain Capital has been paid $50,000 U.S. for these services. Mountain Capital and its directors, officers, and other principals own, in the aggregate, zero shares of the Company as of the date of this post.